Colchicine in Coronary Artery Disease
Low-dose colchicine (0.5 mg daily) is indicated for secondary prevention in patients with coronary artery disease, particularly those with recent myocardial infarction (within 30 days) or stable chronic coronary syndromes, as it reduces myocardial infarction and stroke risk without increasing mortality. 1, 2
Indications and Evidence Base
The 2024 ESC Guidelines provide the strongest recommendation framework. Colchicine 0.5 mg daily should be considered in two specific CAD populations:
Recent Acute Coronary Syndrome
- Timing: Initiate within 30 days of MI (median 14 days in COLCOT trial) 1, 2
- Evidence: COLCOT demonstrated 23% reduction in composite cardiovascular outcomes (HR 0.77; 95% CI 0.61-0.96) 1
- Guideline strength: Class 2b recommendation from 2025 ACC/AHA guidelines 2
Stable Chronic Coronary Syndromes
- Timing: Patients stable for ≥6 months 1
- Evidence: LODOCO2 showed 31% reduction in primary endpoint (HR 0.69; 95% CI 0.57-0.83) 1
- Stronger evidence base: More robust risk reduction than in acute setting
Key efficacy outcomes supported by high-certainty evidence include:
- Myocardial infarction reduction: 26% (RR 0.74; 95% CI 0.57-0.96) 1
- Stroke reduction: 33% (RR 0.67; 95% CI 0.47-0.95) 1
- No mortality benefit demonstrated (all-cause or cardiovascular) 1, 2
Dosing
Standard dose: 0.5 mg once daily (may use 0.6 mg once daily as equivalent) 2, 3
The trials specifically studied 0.5 mg daily, and this is the FDA-approved dose for cardiovascular indication 2. Higher doses provide no additional benefit and increase adverse effects.
Absolute Contraindications
Do not prescribe colchicine if any of the following are present: 2, 3
- Severe renal impairment: CrCl <15 mL/min or dialysis-dependent
- Severe hepatic impairment: Child-Pugh Class C
- Blood dyscrasias: Active bone marrow suppression
- Concurrent use of strong CYP3A4 AND P-glycoprotein inhibitors: Including clarithromycin, ketoconazole, ritonavir, cyclosporine 3
Dose Adjustments for Organ Dysfunction
Renal Impairment 3
- Mild-moderate (CrCl 30-80 mL/min): No dose adjustment required, but monitor closely for adverse effects
- Severe (CrCl <30 mL/min): Start 0.3 mg daily; increase only with close monitoring
- Dialysis: 0.3 mg twice weekly for prophylaxis; single 0.6 mg dose for acute treatment (no repeat within 2 weeks)
Hepatic Impairment 3
- Mild-moderate: No dose adjustment, but monitor closely
- Severe: Consider dose reduction; close monitoring mandatory
Drug Interactions Requiring Dose Modification
Critical interactions that mandate dose reduction to 0.3 mg daily or 0.3 mg every other day 3:
- Strong CYP3A4 inhibitors: Clarithromycin, ketoconazole, itraconazole, ritonavir, atazanavir
- P-glycoprotein inhibitors: Cyclosporine, ranolazine
- Moderate CYP3A4 inhibitors: Diltiazem, verapamil, erythromycin, fluconazole
Do not treat acute gout flares with colchicine in patients already on prophylactic colchicine for CAD 3
Monitoring Recommendations
Before Initiation
- Renal function: Calculate CrCl using Cockcroft-Gault equation 3
- Hepatic function: Assess liver enzymes and synthetic function
- Complete blood count: Baseline for blood dyscrasias
- Medication review: Screen for CYP3A4/P-glycoprotein inhibitors
During Treatment
- Monitor for gastrointestinal symptoms: Diarrhea occurs in ~10% (most common adverse effect) 1
- Pneumonia surveillance: Slightly increased risk (0.9% vs 0.4%) 1
- Periodic CBC: Monitor for bone marrow suppression, especially in renal/hepatic impairment
- Renal/hepatic function: Reassess if clinical status changes
Safety Profile and Common Pitfalls
Gastrointestinal adverse events are the primary concern:
- Diarrhea: 68% increased risk (RR 1.68) but typically mild and transient 4
- Usually self-limited; does not require discontinuation in most cases
- If intolerable, consider dose reduction to 0.3 mg daily rather than complete cessation
Pneumonia risk: Small but statistically significant increase 1
- Monitor for respiratory symptoms
- Consider temporary discontinuation during acute infections
Non-cardiovascular mortality signal: COPS trial showed concerning trend (8 vs 1 deaths) 2
- This has NOT been replicated in larger trials
- Meta-analyses show no overall mortality increase 1, 4
- Likely represents statistical noise from small sample size
Critical pitfall: The CLEAR SYNERGY trial (2025) showed neutral results in acute MI patients undergoing PCI 5
- Suggests colchicine may be less effective during acute phase with intensive pharmaco-invasive therapy
- Optimal timing: Start after acute hospitalization phase, not during index PCI admission
Clinical Decision Algorithm
Start colchicine 0.5 mg daily if:
- Patient has documented CAD (prior MI, stable angina, or proven coronary atherosclerosis)
- CrCl ≥30 mL/min AND no severe hepatic impairment
- Not taking strong CYP3A4/P-gp inhibitors
- No blood dyscrasias
- Patient can tolerate potential GI side effects
Reduce to 0.3 mg daily if:
- CrCl <30 mL/min (but not on dialysis)
- Severe hepatic impairment
- Concurrent moderate CYP3A4 inhibitors
Do not use if:
- CrCl <15 mL/min or dialysis-dependent
- Concurrent strong CYP3A4 AND P-gp inhibitors
- Active blood dyscrasias
Practical Implementation
The 2024 ESC Guidelines provide the most comprehensive framework, showing colchicine reduces MI and stroke without mortality benefit 1. The 2025 ACC/AHA guidelines are more conservative, giving only a Class 2b recommendation ("may be reasonable") 2, reflecting uncertainty about optimal patient selection.
In real-world practice: Prioritize colchicine in stable CAD patients or those 2-4 weeks post-MI who are already on optimal medical therapy (statins, antiplatelet agents, ACE-I/ARBs) but remain at high residual inflammatory risk. The drug is most cost-effective and has the largest absolute benefit in this population 1, 6, 7.
Avoid initiating during acute hospitalization for MI given CLEAR SYNERGY results 5. Instead, start at first post-discharge follow-up visit when patient is clinically stable.